SAM
MCRB icon

Soviero Asset Management’s Seres Therapeutics MCRB Stock Holding History

Soviero Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18,000
Closed -$2.56M – 40
2022
Q1 		$2.56M Sell
18,000
-9,500
-35% -$1.46M 0.63% 30
2021
Q4 		$4.58M Buy
+27,500
New +$4.37M 1.06% 26

Other funds holding MCRB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Soviero Asset Management's MCRB Position: Q2 2022 in Review

Soviero Asset Management sold out of Seres Therapeutics (MCRB) in Q2 2022, closing a stake of 18,000 shares — an estimated $2.56M sold.

Soviero Asset Management first reported a position in MCRB in Q4 2021 and held it in 2 quarters. The position peaked at $4.58M in Q4 2021. 123 funds tracked by Wall St. Rank hold MCRB as of Q2 2022.

  • Soviero Asset Management reported no remaining Seres Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Soviero Asset Management sold 18,000 Seres Therapeutics shares in Q2 2022, an estimated $2.56M.
  • Soviero Asset Management first reported a position in Seres Therapeutics in Q4 2021 and held it in 2 quarters.
  • Soviero Asset Management's Seres Therapeutics position peaked at $4.58M in Q4 2021.
  • 123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2022.

Based on Soviero Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.